References
- MacLennan AH, Henry D, Hill S, Moore V. Oral hormone replacement therapy for general menopausal symptoms (Protocol for a Cochrane Review). In The Cochrane Library, Issue 3, 1999. Oxford: Update Software
- The Writing Group for the PEP Trial. Effects of hormone therapy on bone mineral density. J Am Med Assoc 1996;276:1389–96
- Barrett-Connor E, Grady D. Hormone replace-ment therapy, heart disease and other considerations. Annu Rev Public Health 1998; 19:55–72
- Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997;48:527–535
- Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574–82
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350: 1047–59
- Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1995;191:150–60
- The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61–109
- Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women — principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestogen and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
- Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise — was it inevitable? Climacteric 2002;5:317–25
- Chan J. Response-order effects in Likert-type scales. Educational and Psychological Measure-ment 1991; 51:531–40
- Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225–32
- One year after WHI reports, majority of women still confused and misinformed about the safety of menopausal hormone therapy. New York: Thursday, November 6, 2003 (NWHRC)
- Breslau ES, Davis WW, Doner L, et al. The hormone therapy dilemma: women respond. J Am Med Womens Assoc 2003;58:33–43
- Creasman WT, Hoel D, DiSaia PJ. WHI: Now that the dust has settled: a commentary. Am J Obstet Gynecol 2003;189:621–6
- Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized con-trolled trial. Climacteric 2003;6;302–10
- Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos CT. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 2003;98:1209–28
- Wrensch M, Chew T, Farren G, et al. Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res 2003;5:R88–102